Unleashing the therapeutic potential of apoptotic bodies

Biochem Soc Trans. 2020 Oct 30;48(5):2079-2088. doi: 10.1042/BST20200225.

Abstract

Extracellular vesicles (EVs), membrane-bound vesicles that are naturally released by cells, have emerged as new therapeutic opportunities. EVs, particularly exosomes and microvesicles, can transfer effector molecules and elicit potent responses in recipient cells, making them attractive therapeutic targets and drug delivery platforms. Furthermore, containing predictive biomarkers and often being dysregulated in various disease settings, these EVs are being exploited for diagnostic purposes. In contrast, the therapeutic application of apoptotic bodies (ApoBDs), a distinct type of EVs released by cells undergoing a form of programmed cell death called apoptosis, has been largely unexplored. Recent studies have shed light on ApoBD biogenesis and functions, promisingly implicating their therapeutic potential. In this review, we discuss many strategies to develop ApoBD-based therapies as well as highlight their advantages and challenges, thereby positioning ApoBD for potential EV-based therapy.

Keywords: apoptosis; apoptotic bodies; extracellular vesicles; therapeutics.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Apoptosis*
  • Biomarkers / metabolism*
  • Cell-Derived Microparticles / physiology*
  • Clinical Trials as Topic
  • Drug Delivery Systems
  • Exosomes / metabolism*
  • Extracellular Vesicles / metabolism*
  • Homeostasis
  • Humans
  • Immunotherapy
  • Phagocytes
  • RNA, Small Interfering / metabolism
  • Regeneration*
  • Translational Research, Biomedical
  • Treatment Outcome*

Substances

  • Biomarkers
  • RNA, Small Interfering